Citius Pharmaceuticals, Inc. — Director's Dealing 2016

Jun 29, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Citius Pharmaceuticals, Inc. (CTXR)
CIK: 0001506251
Period of Report: 2016-06-23

Reporting Person: Holuka Eugene Myron (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-06-23	Options to Purchase Common Stock	$0.8	A	200000	Acquired	2026-06-23	Common Stock (200000)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options to Purchase Common Stock	$0.001		Common Stock ()	36212	Direct

Footnotes

F1: On April 14, 2014 the Reporting Person was granted a ten-year option to purchase 20,000 shares of LMB common stock at an exercise price of $0.001 per share. The option vests in 1/3 increments over a three year period commencing on the first anniversary of the date of the grant, or April 14, 2014. On March 30, 2015 the Issuer entered into that certain Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Citius LMB Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of the Issuer and Leonard-Meron Biosciences, Inc., a Delaware corporation ("LMB"). Pursuant to the Merger Agreement, the option was converted into an option to purchase 36,212 shares of the Issuer's common stock at a per share exercise price of $0.001. The option vests in 1/3 increments over a three year period with the first installment vesting on April 14, 2014.

F2: The options vest in full on the first anniversary of the date of grant.